Brian Armstrong

I think a lot of the money that's been made in crypto and AI will actually go into the next moonshots and all of that stuff.

But sorry, your question was about which part again, sorry.

Run a human trial.

Yeah, a lot of trials.

A lot of trials.

I mean, in a software company, most of your costs are people and then some AWS and stuff like that.

In a biotech company, typically it's people and then materials, like reagents and things.

But in this case, now that we're getting ready to go into the clinic, yeah, it's, you know, your average phase one trial might be, I don't know, 10 or 20 million.

And you can kind of go up from there on phase two and phase three.

So you need to get enough shots on goal to get some of these candidates to come out the other side and have a big impact.

So we've got enough capital now to run a number of trials, which is good.

Brian, you want to weigh in?

Yeah, it's a great point.

I mean, I think this is going to happen too.

I think it'll be good for humanity on net.

I think a lot of people will freak out about it for a while, but it's, I think there was a Pew research study.

I saw that something like 80% of Americans would support embryo editing for disease prevention.

So that was more than I expected.

I thought 80% is pretty high, but you know, only about 20%, I think supported it for quote enhancement.

the part that I've never been able to figure out is what's the line between disease prevention and enhancement, right?